LARISSA CELLES: Open Payments
NPI 1902178700 · TORRANCE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,939 in 80 payments from 32 companies in 2025. Trend: 2023 $1,015 · 2024 $1,571 · 2025 $1,939
Food & beverage: $1,939
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $231 |
| E.R. Squibb & Sons, L.L.C. | 14 | $207 |
| Celgene Corporation | 12 | $147 |
| Incyte Corporation | 3 | $84 |
| Karyopharm Therapeutics Inc. | 3 | $82 |
| Genentech USA, Inc. | 3 | $82 |
| Exelixis Inc. | 2 | $80 |
| AstraZeneca Pharmaceuticals LP | 3 | $77 |
| EMD Serono, Inc. | 2 | $72 |
| BeOne Medicines USA, Inc. | 2 | $69 |
Products named: REBLOZYL, ERLEADA, OPDIVO, OPDUALAG, XPOVIO, CABOMETYX, BRUKINSA, Fabhalta.
Industry payments across CA — which companies pay providers there.
